NCT01455571 2014-02-26
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited